Otsuka Pharmaceutical Signs Joint Development Pact With Korean Dong-A
This article was originally published in PharmAsia News
Japanese drug maker Otsuka Pharmaceutical and Dong-A Pharmaceutical of Korea March 30 signed a partnership agreement to jointly research and development new drugs. According to the agreement, the two will cooperate in pharmaceutical R&D and clinic trials. Currently, Otsuka and Dong-A are cooperating in manufacturing and marketing beverage products in Korea. (Click here for more - Japanese language
You may also be interested in...
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
AdvaMed CEO Scott Whitaker shared a letter he sent to member companies voicing support for the ongoing protests around the US against police brutality that were sparked after the killing of George Floyd. “While we continue our single-minded pursuit of medical breakthroughs to treat and cure disease, we must also have a single-minded focus on eradicating the disease of racism in this country and around the world,” Whitaker wrote.